{"changes":[],"country":"GB","description":"CellCentric develops inobrodib, a first-in-class oral small-molecule inhibitor of p300/CBP designed to treat multiple myeloma and other cancers by disrupting cancer cell growth. It targets patients who want effective treatments taken orally in community settings rather than hospitals. The oral approach expands access and reduces healthcare system burden versus complex existing therapies.","domain":"cellcentric.com","employees":null,"founded":2010,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":52.197585,"lng":0.139154,"location":"Cambridge","name":"CellCentric","rounds":[{"amountQuarantined":false,"amountUsd":220000000,"currency":"USD","date":"2026-05-06","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-13","status":"attributed","url":null},"status":"attributed","type":"series-d+","url":null}],"slug":"cellcentric-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-13","status":"attributed","url":null},{"fact":"existence","publisher":"cellcentric.com","retrievedAt":"2026-05-13","status":"self-reported","url":"https://cellcentric.com"},{"fact":"description","publisher":"cellcentric.com","retrievedAt":"2026-05-13","status":"self-reported","url":"https://cellcentric.com"}],"stage":"series-b+","techStack":["Cloudflare","WordPress 6.9.4","Tagembed","Google Analytics","Google Tag Manager","Swiper","jQuery Migrate 3.4.1","Elementor 4.0.8","PHP","DoubleClick Floodlight","CookieYes 3.4.2","Python"],"totalRaisedUsd":300000000,"updatedAt":"2026-05-13"}